(CBMG) |
| 0 (0%) 07-16 12:40 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 43.32 |
| Resistance 1: | 37.09 |
| Pivot price: | 34.45 |
| Support 1: | 32.57 |
| Support 2: | 29.77 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 1.090 |
| Book Value | 1.870 |
| PEG Ratio | 1.80 |
| Gross Profit | 3.758 |
| Profit Margin (%) | 11.96 |
| Operating Margin (%) | 13.27 |
| Return on Assets (ttm) | 13.5 |
| Return on Equity (ttm) | 49.2 |
Company news
Mon, 20 Nov 2023
Rockville’s CBMG Holdings announces name change - Maryland Daily Record
Mon, 20 Nov 2023
CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc. - PR Newswire
Thu, 04 May 2023
Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies - PMLiVE
Thu, 04 May 2023
J&J forks out $245m to develop CAR-T therapies - BioProcess International
Tue, 02 May 2023
J&J Makes $245M Play to Develop Next-Gen CAR-T Therapies - BioSpace
Thu, 30 Sep 2021
CBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor Therapies - PR Newswire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
